Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 
  Users Online: 547 Home Print this page Email this page Small font sizeDefault font sizeIncrease font size  
This article has been cited by
1Multifactorial Basis and Therapeutic Strategies in Metabolism-Related Diseases
João V. S. Guerra,Marieli M. G. Dias,Anna J. V. C. Brilhante,Maiara F. Terra,Marta García-Arévalo,Ana Carolina M. Figueira
2Topiramate-Induced Persistent Eyelid Myokymia
Mohammadrasoul Khalkhali
Case Reports in Psychiatry.2016;2016(8)1
3The risk of cardiovascular complications with current obesity drugs
Ariana M. Chao,Thomas A. Wadden,Robert I. Berkowitz,Kerry Quigley,Frank Silvestry
Expert Opinion on Drug Safety.2020;19(9)1095
4Topiramate as a rare cause of reversible Fanconi syndrome and acute kidney injury: a case report and literature review
Marcelle G. Meseeha,Maximos N. Attia,Victor O. Kolade
Journal of Community Hospital Internal Medicine Perspectives.2016;6(1)30510
5Influence of sibutramine in addition to diet and exercise on the relationship between weight loss and blood glucose changes
Sadaf Kamil,Nicholas Finer,William Philip T James,Ian D. Caterson,Charlotte Andersson,Christian Torp-Pedersen
European Heart Journal - Cardiovascular Pharmacotherapy.2016;6(1)pvw029
6Neurochemical regulators of food behavior for pharmacological treatment of obesity: current status and future prospects
Gayane Sargis Vardanyan,Hasmik Samvel Harutyunyan,Michail Iosif Aghajanov,Ruben Sargis Vardanyan
Future Medicinal Chemistry.2020;12(20)1865
7Investigational glucagon-like peptide-1 agonists for the treatment of obesity
Brian Tomlinson,Miao Hu,Yuzhen Zhang,Paul Chan,Zhong-Min Liu
Expert Opinion on Investigational Drugs.2016;25(10)1167
8Utilisation of the Prestwick Chemical Library to identify drugs that inhibit the growth of mycobacteria
Panchali Kanvatirth,Rose E. Jeeves,Joanna Bacon,Gurdyal S. Besra,Luke J. Alderwick,Sung Jae Shin
PLOS ONE.2019;14(3)e0213713
9Obesity may increase the prevalence of Parkinson’s Disease (PD) while PD may reduce obesity index in patients
Zhong Li Xue,Adebisi Muslimat Kehinde,Liuyi Liuyi,Salim Mzee Said Abdulraman,Mahmud Abdul Nazif,Kanton Aaron Gia,Mustapha Abdullateef Taiye
Journal of Neuroscience and Neurological Disorders.2020;4(1)024
10An evaluation of liraglutide including its efficacy and safety for the treatment of obesity
Chen-Hsiu Lin,Li Shao,Yu-Mei Zhang,Yu-Ju Tu,Yuzhen Zhang,Brian Tomlinson,Paul Chan,Zhongmin Liu
Expert Opinion on Pharmacotherapy.2020;21(3)275
11An evaluation of liraglutide including its efficacy and safety for the treatment of obesity
Silvia Garelli,Nicola Salituro,Giulia M. Pontesilli,Luigi Ricciardiello,Valentina Vicennati,Uberto Pagotto
Expert Opinion on Pharmacotherapy.2019;21(3)464
12Anti-obesity drugs
Wayne Rankin,Gary Wittert
Current Opinion in Lipidology.2015;26(6)536
13Simultaneous determination of barbiturates, phenytoin and topiramate in hair by LC-MS/MS and application to real samples
Jihyun Kim,Junghyun Kim,Hyesun Yum,Moonhee Jang,Jongsook Rhee,Sangki Lee,Sang Beom Han
Journal of Pharmacological and Toxicological Methods.2020;106(6)106931
14Obesity and schizophrenia: New drugs, new hopes
Cedo Miljevic,Olivera Vukovic
Psihijatrija danas.2020;52(1-2)113

Subscribe this journal
Submit articles
Most popular articles
Joiu us as a reviewer
Email alerts
Recommend this journal